Jason Lau
Examiner (ID: 3594, Phone: (571)270-7644 , Office: P/3743 )
Most Active Art Unit | 3762 |
Art Unit(s) | 3762, 3743 |
Total Applications | 965 |
Issued Applications | 457 |
Pending Applications | 112 |
Abandoned Applications | 396 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 9902022
[patent_doc_number] => 20150057222
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-02-26
[patent_title] => 'METHODS OF TREATING CARTILAGE DEFECTS USING A SOLUBLE MORPHOGENIC PROTEIN COMPLEX'
[patent_app_type] => utility
[patent_app_number] => 14/197952
[patent_app_country] => US
[patent_app_date] => 2014-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 46
[patent_figures_cnt] => 46
[patent_no_of_words] => 24412
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 8
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14197952
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/197952 | METHODS OF TREATING CARTILAGE DEFECTS USING A SOLUBLE MORPHOGENIC PROTEIN COMPLEX | Mar 4, 2014 | Abandoned |
Array
(
[id] => 9634316
[patent_doc_number] => 20140212424
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-07-31
[patent_title] => 'ANTI-TNF-ALPHA ANTIBODIES AND THEIR USES'
[patent_app_type] => utility
[patent_app_number] => 14/194090
[patent_app_country] => US
[patent_app_date] => 2014-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 28
[patent_no_of_words] => 26088
[patent_no_of_claims] => 80
[patent_no_of_ind_claims] => 59
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14194090
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/194090 | Anti-TNF-alpha antibodies and their uses | Feb 27, 2014 | Issued |
Array
(
[id] => 10169347
[patent_doc_number] => 09200048
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2015-12-01
[patent_title] => 'High activity growth factor mutants'
[patent_app_type] => utility
[patent_app_number] => 14/182604
[patent_app_country] => US
[patent_app_date] => 2014-02-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 8594
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 108
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14182604
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/182604 | High activity growth factor mutants | Feb 17, 2014 | Issued |
Array
(
[id] => 9537169
[patent_doc_number] => 20140161816
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-06-12
[patent_title] => 'ANTI- TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES'
[patent_app_type] => utility
[patent_app_number] => 14/068010
[patent_app_country] => US
[patent_app_date] => 2014-02-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 18
[patent_no_of_words] => 41926
[patent_no_of_claims] => 101
[patent_no_of_ind_claims] => 41
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14068010
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/068010 | Anti-TNF antibodies, compositions, methods and uses | Feb 17, 2014 | Issued |
Array
(
[id] => 9685307
[patent_doc_number] => 20140242071
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-08-28
[patent_title] => 'M-CSF SPECIFIC MONOCLONAL ANTIBODY AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 14/171330
[patent_app_country] => US
[patent_app_date] => 2014-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 46
[patent_figures_cnt] => 46
[patent_no_of_words] => 49322
[patent_no_of_claims] => 39
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14171330
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/171330 | M-CSF specific monoclonal antibody and uses thereof | Feb 2, 2014 | Issued |
Array
(
[id] => 11311736
[patent_doc_number] => 20160347846
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-12-01
[patent_title] => 'FUSION PROTEINS FOR MODULATING REGULATORY AND EFFECTOR T CELLS'
[patent_app_type] => utility
[patent_app_number] => 14/764024
[patent_app_country] => US
[patent_app_date] => 2014-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 21
[patent_no_of_words] => 26155
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14764024
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/764024 | Fusion proteins for modulating regulatory and effector T cells | Jan 30, 2014 | Issued |
Array
(
[id] => 9635418
[patent_doc_number] => 20140213528
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-07-31
[patent_title] => 'Fibrosuppressant Biotherapeutics'
[patent_app_type] => utility
[patent_app_number] => 14/168900
[patent_app_country] => US
[patent_app_date] => 2014-01-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 22
[patent_no_of_words] => 11311
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14168900
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/168900 | Fibrosuppressant Biotherapeutics | Jan 29, 2014 | Abandoned |
Array
(
[id] => 10567419
[patent_doc_number] => 09290576
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2016-03-22
[patent_title] => 'Antibodies that bind to TL1A and their uses'
[patent_app_type] => utility
[patent_app_number] => 14/146566
[patent_app_country] => US
[patent_app_date] => 2014-01-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 9
[patent_no_of_words] => 31544
[patent_no_of_claims] => 51
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 99
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14146566
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/146566 | Antibodies that bind to TL1A and their uses | Jan 1, 2014 | Issued |
Array
(
[id] => 9602716
[patent_doc_number] => 20140199399
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-07-17
[patent_title] => 'USE OF TGF-BETA ANTAGONISTS TO TREAT INFANTS AT RISK OF DEVELOPING BRONCHOPULMONARY DYSPLASIA'
[patent_app_type] => utility
[patent_app_number] => 14/139332
[patent_app_country] => US
[patent_app_date] => 2013-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 12216
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14139332
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/139332 | USE OF TGF-BETA ANTAGONISTS TO TREAT INFANTS AT RISK OF DEVELOPING BRONCHOPULMONARY DYSPLASIA | Dec 22, 2013 | Abandoned |
Array
(
[id] => 10444599
[patent_doc_number] => 20150329613
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-11-19
[patent_title] => 'FUSION POLYPEPTIDES AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 14/655617
[patent_app_country] => US
[patent_app_date] => 2013-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 13514
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14655617
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/655617 | FUSION POLYPEPTIDES AND USES THEREOF | Dec 19, 2013 | Abandoned |
Array
(
[id] => 10430222
[patent_doc_number] => 20150315234
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-11-05
[patent_title] => 'MYOBLAST DIFFERENTIATION PROMOTER'
[patent_app_type] => utility
[patent_app_number] => 14/382700
[patent_app_country] => US
[patent_app_date] => 2013-12-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3732
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14382700
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/382700 | MYOBLAST DIFFERENTIATION PROMOTER | Dec 11, 2013 | Abandoned |
Array
(
[id] => 11487087
[patent_doc_number] => 09593151
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-03-14
[patent_title] => 'Use of fusion protein'
[patent_app_type] => utility
[patent_app_number] => 14/653276
[patent_app_country] => US
[patent_app_date] => 2013-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 6
[patent_no_of_words] => 7638
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14653276
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/653276 | Use of fusion protein | Dec 4, 2013 | Issued |
Array
(
[id] => 9561888
[patent_doc_number] => 20140179601
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-06-26
[patent_title] => 'FGF-9 AND ITS USE RELATING TO BLOOD VESSELS'
[patent_app_type] => utility
[patent_app_number] => 14/093000
[patent_app_country] => US
[patent_app_date] => 2013-11-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 20
[patent_no_of_words] => 13020
[patent_no_of_claims] => 62
[patent_no_of_ind_claims] => 37
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14093000
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/093000 | FGF-9 AND ITS USE RELATING TO BLOOD VESSELS | Nov 27, 2013 | Abandoned |
Array
(
[id] => 11611539
[patent_doc_number] => 09649383
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-05-16
[patent_title] => 'Liquid formulations for TNFR:Fc fusion proteins'
[patent_app_type] => utility
[patent_app_number] => 14/443557
[patent_app_country] => US
[patent_app_date] => 2013-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 16555
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14443557
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/443557 | Liquid formulations for TNFR:Fc fusion proteins | Nov 14, 2013 | Issued |
Array
(
[id] => 9739767
[patent_doc_number] => 20140275486
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-09-18
[patent_title] => 'HUMAN ANTIBODIES THAT BIND HUMAN TNF-ALPHA AND METHODS OF PREPARING THE SAME'
[patent_app_type] => utility
[patent_app_number] => 14/078181
[patent_app_country] => US
[patent_app_date] => 2013-11-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 14416
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14078181
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/078181 | Human antibodies that bind human TNF-alpha and methods of preparing the same | Nov 11, 2013 | Issued |
Array
(
[id] => 9397009
[patent_doc_number] => 20140094416
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-04-03
[patent_title] => 'SPARC ANGIOGENIC DOMAIN AND METHODS OF USE'
[patent_app_type] => utility
[patent_app_number] => 14/078119
[patent_app_country] => US
[patent_app_date] => 2013-11-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 15535
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14078119
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/078119 | SPARC ANGIOGENIC DOMAIN AND METHODS OF USE | Nov 11, 2013 | Abandoned |
Array
(
[id] => 10110824
[patent_doc_number] => 09146232
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2015-09-29
[patent_title] => 'Method for stabilizing protein'
[patent_app_type] => utility
[patent_app_number] => 14/071584
[patent_app_country] => US
[patent_app_date] => 2013-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4704
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14071584
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/071584 | Method for stabilizing protein | Nov 3, 2013 | Issued |
Array
(
[id] => 10399432
[patent_doc_number] => 20150284441
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-10-08
[patent_title] => 'TGFBeta-derived polypeptides and uses thereof'
[patent_app_type] => utility
[patent_app_number] => 14/440627
[patent_app_country] => US
[patent_app_date] => 2013-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 5697
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14440627
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/440627 | TGFβ-derived polypeptides and uses thereof | Oct 29, 2013 | Issued |
Array
(
[id] => 9569173
[patent_doc_number] => 20140186887
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-07-03
[patent_title] => 'RECEPTOR ACTIVATOR OF NF-kappaB'
[patent_app_type] => utility
[patent_app_number] => 14/065133
[patent_app_country] => US
[patent_app_date] => 2013-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 27893
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14065133
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/065133 | RECEPTOR ACTIVATOR OF NF-kappaB | Oct 27, 2013 | Abandoned |
Array
(
[id] => 11698854
[patent_doc_number] => 09688757
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-06-27
[patent_title] => 'Bi-specific affinity reagents for cell-lineage-specific TNF-alpha neutralization'
[patent_app_type] => utility
[patent_app_number] => 14/438288
[patent_app_country] => US
[patent_app_date] => 2013-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 18
[patent_no_of_words] => 13936
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14438288
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/438288 | Bi-specific affinity reagents for cell-lineage-specific TNF-alpha neutralization | Oct 27, 2013 | Issued |